These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11716804)

  • 1. Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
    Kubota E; Dean RG; Hubner RA; Balding LC; Johnston CI; Burrell LM
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S31-3. PubMed ID: 11716804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
    [No Abstract]   [Full Text] [Related]  

  • 3. Vasopeptidase inhibition: effective blood pressure control for vascular protection.
    Quaschning T; Ruschitzka F; Lüscher TF
    Curr Hypertens Rep; 2002 Feb; 4(1):78-84. PubMed ID: 11790296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibitors.
    Sagnella GA
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):90-5. PubMed ID: 12228848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vasopeptidase inhibitors. Clinical implications of a new class of drugs].
    Quaschning T; Corti R; Ruschitzka FT; Noll G; Lüscher TF
    Dtsch Med Wochenschr; 2000 Apr; 125(16):499-503. PubMed ID: 10819011
    [No Abstract]   [Full Text] [Related]  

  • 7. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
    Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
    Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibition and endothelial function in hypertension.
    d'Uscio LV; Lüscher TF
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S6-14. PubMed ID: 11716800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
    Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of peptidases in the control of blood pressure.
    Kubota E; Dean RG; Balding LC; Burrell LM
    Essays Biochem; 2002; 38():129-39. PubMed ID: 12463166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
    Chen HH; Cataliotti A; Burnett JC
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
    Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
    Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopeptidase inhibitors--concepts and evidence.
    Ruschitzka F; Corti R; Quaschning T; Hermann M; Lüscher TF
    Nephrol Dial Transplant; 2001 Aug; 16(8):1532-5. PubMed ID: 11477147
    [No Abstract]   [Full Text] [Related]  

  • 16. Vasopeptidase inhibitors.
    Weber MA
    Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
    Nathisuwan S; Talbert RL
    Pharmacotherapy; 2002 Jan; 22(1):27-42. PubMed ID: 11794428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure.
    Packer M; McMurray JJV
    Lancet; 2017 May; 389(10081):1831-1840. PubMed ID: 27919443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats.
    Cheng ZJ; Grönholm T; Louhelainen M; Finckenberg P; Merasto S; Tikkanen I; Mervaala E
    J Hypertens; 2005 Sep; 23(9):1757-70. PubMed ID: 16093923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.